Welcome to our dedicated page for Soleno Therapeutics SEC filings (Ticker: SLNO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for Soleno Therapeutics, Inc. (NASDAQ: SLNO) provides access to the company’s official regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Soleno describes itself as a biopharmaceutical company focused on novel therapeutics for rare diseases, and its filings document financial results, material agreements, governance changes, and other significant events related to this business.
Investors can review current reports on Form 8-K in which Soleno announces quarterly and preliminary financial results, operating metrics for VYKAT XR (diazoxide choline) extended-release tablets, and updates on the U.S. launch of this once-daily oral treatment for hyperphagia in adults and pediatric patients 4 years of age and older with Prader-Willi syndrome. These filings incorporate press releases that discuss product revenue, profitability, cash balances, and other financial information.
Filings also describe capital structure and financing arrangements, including an accelerated share repurchase (ASR) Agreement with Jefferies LLC for up to $100 million of common stock and a first amendment to Soleno’s loan and security agreement with Oxford Finance LLC and other lenders. The 8-Ks outline key terms of these arrangements, such as prepayment of the purchase price, initial share delivery, and changes to loan availability.
Additional 8-Ks cover corporate governance and Board composition, such as the appointment of an independent director with extensive biopharmaceutical finance experience and the associated equity grants under the company’s equity incentive plan. Other filings provide Regulation FD disclosures on topics like investor presentations and safety-related communications, including Soleno’s description of a serious adverse event reported in the FDA’s FAERS database and its assessment of that event.
On this page, AI-powered tools can help summarize lengthy exhibits and press releases attached to Soleno’s filings, highlight key terms in material agreements, and clarify the implications of reported financial metrics, capital transactions, and governance changes for users reviewing SLNO’s regulatory history.
Soleno Therapeutics entered an accelerated share repurchase with Jefferies to repurchase $100.0 million of common stock. The Company prepaid $100.0 million and received an initial delivery of 1,511,553 shares, with any remaining shares expected by the end of its first fiscal quarter of 2026. The final share count will be based on the stock’s volume‑weighted average price during the program, less an agreed discount, with settlement adjustments that could require either party to deliver additional shares or, in Soleno’s case, make a cash payment.
In connection with the ASR, Soleno amended its Oxford Finance loan agreement to permit the repurchase and to modify previously committed capacity. Lenders are no longer obligated to fund the $25.0 million Term C Loans or $25.0 million Term D Loans. After the amendment, the remaining $100.0 million of loans is uncommitted and may be made available only upon mutual agreement.
Soleno Therapeutics (SLNO) reported its first profitable quarter as a commercial company. For Q3 2025, product revenue was $66.0 million, driving operating income of $22.1 million and net income of $26.0 million. Year-to-date, product revenue reached $98.7 million. The company began recognizing sales after the FDA approved VYKAT XR in March 2025 to treat hyperphagia in Prader-Willi syndrome and first prescriptions shipped in April.
Liquidity strengthened significantly: cash and cash equivalents were $246.7 million and marketable securities were $309.4 million at September 30, 2025. In July, Soleno completed an underwritten offering of 2,705,882 shares at $85.00 per share for gross proceeds of $230.0 million (approximately $14.3 million in offering costs). Long-term debt outstanding was $50.0 million under the Oxford facility, with additional tranches available subject to terms. Shares outstanding were 53,710,025 as of October 31, 2025.
Soleno Therapeutics (SLNO) disclosed a director equity award. On 10/13/2025, the reporting person was granted 10,046 restricted stock units (RSUs) at $0. Each RSU represents the right to receive one share of common stock.
Vesting: one-third on October 13, 2026 and on each one-year anniversary thereafter, subject to continued service. Beneficial ownership following the grant was 10,046 shares, held directly.
Soleno Therapeutics (SLNO)no securities beneficially owned, with no non-derivative or derivative holdings listed. It was filed by one reporting person and includes an Exhibit 24 Power of Attorney authorizing the signatory.
Soleno Therapeutics (SLNO) expanded its Board and Audit Committee by one seat and appointed Mark W. Hahn as a Class II director, with a term expiring at the 2028 annual meeting. Hahn also joins the Audit Committee.
Hahn brings nearly 30 years of CFO experience, including roles at Verona Pharma (through its first product launch and its approximately $10 billion acquisition by Merck in Oct 2025), Dova Pharmaceuticals (acquired by Sobi for up to $915 million in 2019), and Cempra (led IPO and follow-ons). In connection with his appointment, he received 10,046 RSUs, vesting one-third on Oct 13, 2026 and on each annual anniversary thereafter.
Form 144 filed for Soleno Therapeutics, Inc. (SLNO) reports a proposed sale of 1,347,522 shares of common stock, representing approximately 2.54% of the 53,145,009 shares outstanding. The filing shows an approximate sale date of 08/11/2025 through BTIG, LLC on NASDAQ with an aggregate market value of $110,696,581.49. The shares were acquired in two lots: 860,980 shares purchased from the issuer on 06/26/2020 for cash, and 486,542 shares acquired upon net exercise of warrants on 08/11/2025 with payment dated 03/31/2022 noted for the latter lot. The filer certifies no undisclosed material adverse information and declares no sales in the past three months.
Soleno Therapeutics, Inc. Schedule 13G/A reports that Nantahala Capital Management, LLC and its managing members, Wilmot B. Harkey and Daniel Mack, may be deemed beneficial owners of 1,001,350 shares of Soleno common stock as of June 30, 2025. That holding represents 1.99% of the class. The filing states the shares are held by funds and separately managed accounts under Nantahala’s control and that the positions were acquired and are held in the ordinary course of business, not to influence control.
FAQ
What is the current stock price of Soleno Therapeutics (SLNO)?
What is the market cap of Soleno Therapeutics (SLNO)?
